LIGHTHOUSE

A phase 3 multicenter, randomized, double-blind, placebo controlled study to determine the efficacy and safety of BIIB122/DNL151 in participants with Parkinson's Disease and pathogenic LRRK2 variants

Topic / Pathology

  • Parkinson's Disease

Objectives

To have more informations, click on the link below: 

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale - Full Text View - ClinicalTrials.gov

Sponsor

BIOGEN

Status

Early termination

Participating centers

Share

Updated on 06 July 2023